Loading
Life sciences · Journal article
International Journal of Nanomedicine · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract: Spherical nucleic acids (SNAs) are a unique class of nucleic acid nanotherapeutics characterized by densely packed, radially arranged oligonucleotides surrounding a nanoparticle or molecular core, or core-free nanoscale structures. Compared with conventional linear nucleic acids, SNAs exhibit excellent cellular uptake, resistance to nuclease degradation, and efficient target recognition without the help of transfection agents. This review summarizes SNAs’ structural diversity, design principles, and the multiscale delivery barriers they encounter. We mainly focus on liposomal SNAs (LSNAs) as programmable platforms for cancer immunotherapy. We emphasize how lipid chemistry, membrane architecture, and anchor stability control lymphoid distribution, immune-cell uptake, antigen presentation, and strong antitumor immunity, rather than seeing lipids as inert carriers. Furthermore, we also discuss current developments in gene silencing, CRISPR-based genome editing, and stimulus-responsive multimodal therapies, highlighting the significant therapeutic advancements of SNAs like clinical trial NU-0129 and LSNAs like cavrotolimod. Finally, we describe present translational obstacles and potential prospects by using SNAs as next-generation precision immunotherapeutics. Keywords: spherical nucleic acids, liposomal SNAs, tumor targeting, cancer immunotherapy, gene regulation